A Phase 2 Study to Assess the Efficacy and Safety of TGR-1202 (Umbralisib) Monotherapy in Patients With Non-Follicular Indolent Non-Hodgkin's Lymphoma
Latest Information Update: 27 Jun 2023
At a glance
- Drugs Umbralisib (Primary)
- Indications Marginal zone B-cell lymphoma; Non-Hodgkin's lymphoma; Waldenstrom's macroglobulinaemia
- Focus Therapeutic Use
- Sponsors TG Therapeutics Inc
- 13 May 2022 Status changed from active, no longer recruiting to completed.
- 23 Sep 2021 According to a TG Therapeutics Inc media release, data from pooled safety analysis of NCT02793583, NCT01767766, NCT03207256 and NCT03364231 studies has been published in the Blood Advances, a journal of the American Society of Hematology.
- 23 Sep 2021 Results presented in the TG Therapeutics Inc Media Release.